Harmonizome 3.0

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term glycyrrhetinic in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical 18alpha-glycyrrhetinic acid from the curated CTD Gene-Chemical Interactions dataset.

From CTD Gene-Chemical Interactions

genes/proteins interacting with the chemical Glycyrrhetinic Acid from the curated CTD Gene-Chemical Interactions dataset.

From HMDB Metabolites of Enzymes

interacting proteins for the Glycyrrhetinic acid metabolite from the curated HMDB Metabolites of Enzymes dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_A-172 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SNU-423 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_HT-29 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_AsPC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_A498 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_CFPAC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_HOP62 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_J82 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_RKO drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H2122 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_A549 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H1792 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_Panc 03.27 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_HCT15 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_HepG2/C3A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SW 1271 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SW48 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H23 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SW480 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H2030 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_C32 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_CHP-212 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H596 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_HEC-1-A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_RPMI-7951 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_HS-578T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SW 900 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H460 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SHP-77 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_MIA PaCa-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_BT-474 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H2347 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_PANC-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SW1417 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SK-MEL-2 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_KATO III drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SNU-1 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_LoVo drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_H4 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H661 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_SW 1088 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_C-33 A drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_NCI-H1573 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_Hs 766T drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_LS 180 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_COLO 205 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_AN3 CA drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_hTERT-HPNE drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_A-427 drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From Tahoe Therapeutics Tahoe 100M Perturbation Atlas

genes differentially expressed following the 18β-Glycyrrhetinic acid_LOX-IMVI drug perturbation from the Tahoe Therapeutics Tahoe 100M Perturbation Atlas dataset.

From DGIdb Drug Targets 2026

interacting proteins for the GLYCYRRHETINIC ACID drug from theDGIdb Drug Targets 2026 dataset.